Analysts Expect Novavax, Inc. (NVAX) to Announce -$0.18 EPS

Recent Technical Snapshot on Novavax, Inc.

Novavax, Inc. (NVAX) has a market capitalization of 308.05 Million which suggests the company is a huge company further suggesting that the shares of Novavax, Inc. Typically, they estimate what the company's earnings and cash flow will be for the next couple of years, and then apply a ratio - such as a price-to-earnings ratio - to those estimates to determine what the future stock price should theoretically be.

If you look at the company's income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, NVAX earned gross profit of 15.67 Million, in 2015 0 gross profit, while in 2016 Novavax, Inc. Its long-term annual earnings per share (EPS) growth estimated to reach at 14.43% in next 5 years. What do this target means? Analysts predict that Novavax, Inc. will post ($0.62) earnings per share for the current fiscal year. It has a return on equity (ROE) of -787.40%.

Novavax Inc (NASDAQ:NVAX)'s revenue estimates for the current quarter are $5.7 Million according to 6 number of analysts, for the current quarter the company has high revenue estimates of $6.6 Million in contradiction of low revenue estimates of $4.5 Million.

While trading at volume above than average, The Dow Chemical Company (NYSE:DOW) previous 52-week high was $64.96 and moved up 20.79% over the same period, trading at a volume of 7.34 million. The firm's revenue for the quarter was down 7.7% compared to the same quarter past year.

02/28/2017 - Novavax, Inc. had its "neutral" rating reiterated by analysts at Chardan Capital.

Volatility of the shares is also to be considered while making the investment decisions.

Before looking at the financial values or the trading statistics of Novavax, Inc. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $2.00 target price on shares of Novavax in a report on Wednesday, March 1st. Finally, FBR & Co reaffirmed an "outperform" rating and issued a $12.00 target price on shares of Novavax in a report on Wednesday, January 18th. This is built on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell. Price targets frequently change, depending on the outlook for a company's earnings.

Hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. increased its stake in Novavax by 110.5% in the third quarter. Over the last three months, insiders have purchased 105,000 shares of company stock worth $90,800. (NVAX) has a trading volume of 7.41 Million shares, with an average trading volume of 12980 shares - with shares dropping to a 52 week low of $0.73, and the company's shares hitting a 52 week high of $ 8.49.

COPYRIGHT VIOLATION NOTICE: "State Board of Administration of Florida Retirement System Has $179,000 Position in Novavax, Inc". Approximately 22.2% of the company's stock are short sold. Two Sigma Securities LLC acquired a new position in shares of Novavax during the third quarter valued at approximately $751,000. Earnings per share serves as an indicator of a company's profitability.

In recent trading day Novavax, Inc. Piermont Capital Management Inc. now owns 158,788 shares of the biopharmaceutical company's stock worth $330,000 after buying an additional 13,370 shares in the last quarter. Latest closing price was -2.85% below its 50-day moving average and -56.05% below its 200-day moving average. (NVAX) touched the day high at $1.111 while its day Low was at $1.02.

Latest News